How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cell and Advanced Therapies Supply Chain Management Market
- By Therapy Type: Autologous Cell Therapy, Allogeneic Cell Therapy, Gene Therapy, Tissue Engineering, Regenerative Medicine
- By Supply Chain Service: Cold Chain Logistics, Cryopreservation Services, Inventory Management, Transportation and Distribution, Packaging Solutions
- By End User: Hospitals and Clinics, Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Research and Academic Institutions, Specialized Cell Therapy Centers
- By Product Type: Cryogenic Storage Equipment, Temperature Monitoring Devices, Specialized Packaging Materials, Tracking and Traceability Solutions, Automated Handling Systems
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Autologous Cell Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Cell and Advanced Therapies Supply Chain Management Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Catalent Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Cryoport Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Cytiva (part of Danaher Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →BioLife Solutions Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Paragon Bioservices (a part of Catalent)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Vitaeris Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Asymptote Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →BioCision Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Polaris Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →BioStorage Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →NantCell Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cytothera
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Autologous Cell Therapy61.1
- Allogeneic Cell Therapy7.2
- Gene Therapy15.0
- Tissue Engineering8.4
- Regenerative Medicine8.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific9.8
- Catalent Inc.24.5
- Cryoport Inc.10.8
- Sartorius AG10.5
- Lonza Group AG10.9
- Cytiva (part of Danaher Corporation)5.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe25.3
- Asia Pacific19.5
- Latin America12.7
- Middle East and Africa10.3
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 84 | 90 | 75 | 98 | 83 | 87 | 86 |
| Catalent Inc. | 70 | 81 | 72 | 78 | 76 | 69 | 74 |
| Cryoport Inc. | 79 | 76 | 83 | 63 | 80 | 81 | 77 |
| Sartorius AG | 70 | 69 | 79 | 59 | 67 | 67 | 69 |
| Lonza Group AG | 55 | 69 | 75 | 64 | 71 | 71 | 68 |
| Cytiva (part of Danaher Corporation) | 53 | 60 | 53 | 51 | 49 | 56 | 54 |
| BioLife Solutions Inc. | 64 | 43 | 57 | 60 | 42 | 51 | 53 |
| Paragon Bioservices (a part of Catalent) | 46 | 38 | 46 | 43 | 43 | 60 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Catalent Inc.
- Cryoport Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Catalent Inc. | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| Cryoport Inc. | ✓ | ✓ | ◐ | − | ◐ | ◐ |
| Sartorius AG | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Lonza Group AG | − | ◐ | ◐ | ◐ | ◐ | − |
| Cytiva (part of Danaher Corporation) | ◐ | ◐ | ◐ | − | − | − |
| BioLife Solutions Inc. | ✓ | − | ◐ | − | − | − |
| Paragon Bioservices (a part of Catalent) | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Challenger4
Strong scale, closing on the leaders.
Niche3
Specialists in a single segment or region.
Go-to-market strategy
Land Therapy Type in North America, then scale across Cell and Advanced Therapies Supply Chain Management Market — a $130M beachhead inside a $1.77B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Autologous Cell Therapy
Best fit — highest urgency & budget in Therapy Type.
Allogeneic Cell Therapy
Strong fit — clear ROI and a fast path to value.
Gene Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Supply Chain Service & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cell and Advanced Therapies Supply Chain Management Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Cell and Advanced Therapies Supply Chain Management Market is a durable-growth opportunity — $4.05B by 2033, compounding at 6.0%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.0% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Supply Chain Service optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Cell and Advanced Therapies Supply Chain Management Market — a $4.81B market by 2033. Plan: grow share from 9.1% to 17.5%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 17.5% | Behind |
| Revenue | $421M | $842M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 34.4% | 43.8% | At risk |
| Customer retention | 90.4% | 95.4% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Supply Chain Service capability
A defensible second engine — invest in Supply Chain Service to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Supply Chain Service
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $123M capacity & capability investment
- Greenlight bolt-on M&A in Supply Chain Service
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Sales deck · value proposition
Win the Cell and Advanced Therapies Supply Chain Management Market conversation — a $6.64B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cell and Advanced Therapies Supply Chain Management Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Cell and Advanced Therapies Supply Chain Management Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Cell Analysis Systems Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCell Analysis Solution Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportCell Analysis Software Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportCell Analysis Reagents and Consumables Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportCell Activity Assay Service Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportCeliac Test Market
Market size, share, segmentation and regional forecast.
$762M market · 2025 base year
View reportCeliac Disease Testing Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportCeliac Disease Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportCeliac Disease Diagnostics Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportCelecoxib Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCelecoxib Capsule Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportCelecoxib API Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy